மின் மின்மறுப்பு ஸ்பெக்ட்ரோஸ்கோபி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மின் மின்மறுப்பு ஸ்பெக்ட்ரோஸ்கோபி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மின் மின்மறுப்பு ஸ்பெக்ட்ரோஸ்கோபி Today - Breaking & Trending Today

SciBase - Interim report


SciBase - Interim report
January 1 - March 31, 2021
The first quarter in figures
Net sales amounted to TSEK 2,562 (2,469).
The loss after tax amounted to TSEK 8,153 (8,936).
The loss per share amounted to SEK 0.15 (0.54).
The cash flow from current operations was negative in the amount of TSEK 9,473 (7,893).
The gross margin reached 52.7% (54.0%).
Electrode sales volume increased by 14% and reached 7,496 (6,562) units, a new quarterly high. Repeat sales of electrodes to existing customers increased by 18%.
Important events during the quarter
Covid-19 continues to affect sales and the market situation remains difficult to predict going forward, due to ongoing lockdowns and reduced marketing activities. Sales in the company s key market Germany increased by 3%(cleared for currency effects +9%) while overall sales increased by 3% (cleared for currency effects +9%). ....

United States , Matt Leavitt , David Melin , Cezmi Akdis , Simon Grant , Scibase Holding , Swiss Institute Of Allergy , Asthma Research , First Coast Service Options , Medical Device Regulation , Non Melanoma Skin Cancer , Professor Cezmi Akdis , Nature Reviews , Swiss Institute , European Journal , Clinical Immunology , Michael Col , Electrical Impedance Spectroscopy , Artificial Intelligence , Base Holding , First North Growth Market , ஒன்றுபட்டது மாநிலங்களில் , மேட் லெவிட் , டேவிட் மெலின் , சிமோன் மானியம் , சுவிஸ் நிறுவனம் ஆஃப் ஒவ்வாமை ,

SciBase launches Non-melanoma Skin cancer indication for Nevisense


Share this article
STOCKHOLM, May 11, 2021 /PRNewswire/
 SciBase Holding AB ( SciBase ) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the launch of the new Non-Melanoma Skin Cancer (NMSC) clinical application following the completion of their MDR certification process.
SciBase s strategy is to leverage the Nevisense technology platform to launch additional clinical applications and products. The first clinical application or indication to be added is NMSC, initially for Nevisense 3.0.
There are two types of skin cancer: melanoma and non-melanoma skin cancer (NMSC). NMSC is more than ten times more prevalent than melanoma and comes itself in primarily two forms: basal cell carcinoma and squamous cell carcinoma. Although NMSC is less harmful and deadly than melanoma, it is still important that it is detected early and is managed with the most appropriate therapy. Because Dermatologists see many more ....

United States , Simon Grant , Scibase Holding , Prnewswire Scibase Holding Ab , Non Melanoma Skin Cancer , Electrical Impedance Spectroscopy , Artificial Intelligence , Base Holding , First North Growth Market , ஒன்றுபட்டது மாநிலங்களில் , சிமோன் மானியம் , அல்லாத மெலனோமா தோல் புற்றுநோய் , மின் மின்மறுப்பு ஸ்பெக்ட்ரோஸ்கோபி , செயற்கை உளவுத்துறை , அடித்தளம் வைத்திருத்தல் , முதல் வடக்கு வளர்ச்சி சந்தை ,